A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Colon | Rectum
What is the purpose of this trial?
This randomized phase 1b/2 open-label study will evaluate the efficacy of etrumadenant (AB928) treatment combinations in patients with metastatic colorectal cancer.
- Trial withArcus Biosciences, Inc.
- Start Date01/12/2022
- End Date09/20/2023
- Last Updated01/13/2022
- Study HIC#2000029908